Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy

J Thorac Oncol. 2017 Nov;12(11):e175-e177. doi: 10.1016/j.jtho.2017.06.002. Epub 2017 Jun 10.

Authors

Deepa Rangachari¹, Xiuning Le¹, Meghan Shea¹, Mark S Huberman¹, Paul A VanderLaan², Susumu S Kobayashi¹, Daniel B Costa³

Affiliations

¹ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
² Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
³ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: dbcosta@bidmc.harvard.edu.

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Anaplastic Lymphoma Kinase
Crizotinib
Disease-Free Survival
Female
Gene Rearrangement
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / enzymology
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Precision Medicine
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
Receptor Protein-Tyrosine Kinases / genetics*
Receptor Protein-Tyrosine Kinases / metabolism
Survival Rate

Substances

Protein Kinase Inhibitors
Pyrazoles
Pyridines
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases

Grants and funding